Loading...
Market
How much additional funding will Myricx Pharma secure by mid-2025?
3
Resolution / Starting Odds
Less than £50 million • 25%
£50 million to £100 million • 25%
£100 million to £150 million • 25%
More than £150 million • 25%
Official announcements from Myricx Pharma or financial news outlets
Story
London-Based Myricx Pharma Raises £90 Million in 2024 Series A for Cancer Drug Development
Jul 8, 2024, 05:42 AM
British biotech spinout Myricx Pharma, based in London, has successfully raised £90 million ($115 million) in a series A financing round in 2024. The funding, which is one of the largest in recent years in the UK, includes contributions from investors such as the controlling shareholder of Ozempic maker Novo Nordisk and SofinnovaVC. The capital will be utilized to advance Myricx's novel N-myristoyltransferase (NMT) inhibitor antibody-drug conjugates (NMTi-ADC) therapeutics into clinical development. CEO Robin Carr highlighted the company's innovative NMT payload approach to ADCs. This significant investment underscores the growing interest and commitment to cancer treatment advancements.
View original story
Similar markets
Less than €10M • 25%
Between €10M and €20M • 25%
Between €20M and €30M • 25%
More than €30M • 25%
No additional funding • 25%
Up to $10 million • 25%
$10 million to $50 million • 25%
Over $50 million • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Less than $50M • 25%
$50M - $100M • 25%
$100M - $150M • 25%
More than $150M • 25%
Less than $150M • 25%
$150M - $200M • 25%
$200M - $250M • 25%
More than $250M • 25%
Less than $1 billion • 25%
$1 billion to $5 billion • 25%
$5 billion to $10 billion • 25%
More than $10 billion • 25%
Less than $25 million • 25%
$25 million to $50 million • 25%
$50 million to $75 million • 25%
More than $75 million • 25%